OrganiGram (OGI) Q1 2025 earnings summary

Executive summary

• Net revenue grew 17% year-over-year to $42.7 million in Q1 F2025, driven by recreational and international sales, and Motif acquisition contributions.

• Adjusted EBITDA increased to $1.4 million from $0.1 million year-over-year, with adjusted gross margin improving to $14.3 million or 33%.

• Motif Labs acquisition completed, positioning the company as Canada's largest recreational cannabis company by market share.

• SHRED and BOXHOT brands achieved over $385 million in retail sales over the last 12 months.

• Pro-forma cash position of $113 million and negligible debt, bolstered by British American Tobacco (BAT) investment.

Financial highlights

• Gross revenue for Q1 F2025 was $66.8 million, up 19% year-over-year; net revenue reached $42.7 million, up 17%.

• Adjusted gross margin increased to $14.3 million (33% margin), and adjusted EBITDA grew to $1.4 million.

• Net loss widened to $23.0 million from $15.8 million, mainly due to higher fair value loss on BAT top-up rights.

• Cash at December 31, 2024, was $71.2 million; pro-forma cash position expected to be $113 million after BAT investment.

• Working capital stood at $162.5 million, with negligible debt and total assets of $479.2 million.

Outlook and guidance

• Over $10 million in annual run-rate synergies from Motif integration expected within 24 months.

• Final BAT investment tranche of $41.5 million expected to close in February 2025, further strengthening liquidity.

• EU-GMP certification anticipated soon, supporting international expansion and higher-margin sales.

• Continued focus on innovation, operational efficiency, and international expansion.